Treuer Adriana V, Faúndez Mario, Ebensperger Roberto, Hovelmeyer Erwin, Vergara-Jaque Ariela, Perera-Sardiña Yunier, Gutierrez Margarita, Fuentealba Roberto, González Daniel R
Department of Basic Biomedical Sciences, School of Health Sciences, Universidad de Talca, Avenida Lircay s/n, Talca 3460000, Chile.
Departamento de Farmacia, Escuela de Química y Farmacia, Facultad de Química y de Farmacia, Pontificia Universidad Católica de Chile, Av. Vicuña Mackenna 4860, Santiago 7820436, Chile.
Antioxidants (Basel). 2023 Jul 18;12(7):1441. doi: 10.3390/antiox12071441.
NADPH oxidase (NOX2) is responsible for reactive oxygen species (ROS) production in neutrophils and has been recognized as a key mediator in inflammatory and cardiovascular pathologies. Nevertheless, there is a lack of specific NOX2 pharmacological inhibitors. In medicinal chemistry, heterocyclic compounds are essential scaffolds for drug design, and among them, indole is a very versatile pharmacophore. We tested the hypothesis that indole heteroaryl-acrylonitrile derivatives may serve as NOX2 inhibitors by evaluating the capacity of 19 of these molecules to inhibit NOX2-derived ROS production in human neutrophils (HL-60 cells). Of these compounds, and exhibited concentration-dependent inhibition of NOX2 (IC~1 µM). These molecules also reduced NOX2-derived oxidative stress in cardiomyocytes and prevented cardiac damage induced by ischemia-reperfusion. Compound significantly reduced the membrane translocation of p47, a cytosolic subunit that is required for NOX2 activation. Molecular docking analyses of the binding modes of these molecules with p47 indicated that and interact with specific residues in the inner part of the groove of p47, the binding cavity for p22. This combination of methods showed that novel indole heteroaryl acrylonitriles represent interesting lead compounds for developing specific and potent NOX2 inhibitors.
烟酰胺腺嘌呤二核苷酸磷酸氧化酶(NOX2)负责中性粒细胞中活性氧(ROS)的产生,并且已被公认为炎症和心血管疾病中的关键介质。然而,目前缺乏特异性的NOX2药理抑制剂。在药物化学中,杂环化合物是药物设计的重要骨架,其中吲哚是一种非常通用的药效基团。我们通过评估19种此类分子抑制人中性粒细胞(HL-60细胞)中NOX2衍生的ROS产生的能力,来检验吲哚杂芳基丙烯腈衍生物可能作为NOX2抑制剂的假设。在这些化合物中,[具体化合物1]和[具体化合物2]表现出对NOX2的浓度依赖性抑制(IC~1 µM)。这些分子还降低了心肌细胞中NOX2衍生的氧化应激,并预防了缺血再灌注诱导的心脏损伤。化合物[具体化合物3]显著降低了p47的膜转位,p47是NOX2激活所需的胞质亚基。对这些分子与p47结合模式的分子对接分析表明,[具体化合物1]和[具体化合物2]与p47凹槽内部的特定残基相互作用,p22的结合腔就在此处。这些方法的结合表明,新型吲哚杂芳基丙烯腈是开发特异性强效NOX2抑制剂的有趣先导化合物。